Opinion|Videos|January 19, 2026
Data for Duvelisib Plus Chidamide/CHOP in Newly Diagnosed AITL
Author(s)Francine Foss, MD, Matthew Lunning, DO, FACP
Francine Foss, MD, and Matthew Lunning, DO, FACP, discuss findings for duvelisib plus chidamide and CHOP in newly diagnosed angioimmunoblastic T-cell lymphoma.
Advertisement
Episodes in this series
Francine Foss, MD, and Matthew Lunning, DO, FACP, discuss emerging data evaluating duvelisib (Copiktra) in combination with chidamide and CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with newly diagnosed angioimmunoblastic T-cell lymphoma (AITL). They review early efficacy signals and safety considerations associated with this combination strategy. Foss and Lunning consider how these findings may support novel frontline approaches in AITL.
Advertisement
Related to this article
A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.
Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.
Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.
Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.
Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.
Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.
Advertisement
Advertisement
Trending on OncLive
1
Dr Orloff on Key Findings From the Phase 2/3 OptimUM-02 Trial in Uveal Melanoma
2
Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS
3
Study Identifies RNA Surveillance Defect That Fuels Melanoma Through Endogenous Retroviral RNA
4
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
5